-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA GRANTS ACCELERATED APPROVAL TO BAYER’S HYRNUO® (SEVABERTINIB) AS A FIRST-LINE TARGETED THERAPY FOR PATIENTS WITH HER2-MUTATED NON-SMALL CELL LUNG CANCER

Reuters·09/10/2026 02:21:00

Please log in to view news